Drug Profile
Fibroblast growth factor agonist - Johnson & Johnson Pharmaceutical Research and Development LLC
Alternative Names: FGF-3DPLatest Information Update: 12 Mar 2008
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Class Small molecules
- Mechanism of Action Fibroblast growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery restenosis; Pressure ulcer; Solid tumours; Stroke; Vascular disorders
Most Recent Events
- 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson
- 24 Jun 2001 No-Development-Reported for Decubitus ulcer in USA (Unknown route)
- 24 Jun 2001 No-Development-Reported for Stroke in USA (Unknown route)